Business Context and Reporting Period
This Form 8-K Current Report was filed by Allarity Therapeutics, Inc. on January 12, 2023. The filing discloses the entry into new employment agreements with Chief Executive Officer James G. Cullem and Chief Financial Officer Joan Brown. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Compensation Terms
The filing does not provide revenue, profit, cash flow, or debt metrics. It details specific compensation terms contingent on a future financing event:
- James G. Cullem (CEO): Annual base salary of $425,000 (as of Jan 1, 2023), with an option to defer up to $30,000 in restricted stock. Eligible for an annual bonus up to 50% of base salary.
- Joan Brown (CFO): Annual base salary of $250,000 (as of Jan 1, 2023). Eligible for an annual bonus up to 40% of base salary.
- Equity Grants: Contingent on a "New Financing" of at least $7 million. Cullem is eligible for options covering 3.5% of post-financing shares (vesting over 48 months) plus an additional 2.0% upon completion of a Phase 2 clinical trial. Brown is eligible for options covering 0.75% of post-financing shares (vesting over 48 months).
- Severance: Cullem is entitled to 12 months of salary continuation upon termination without Cause or Change-of-Control. Brown is entitled to 5 months of salary continuation under similar conditions.
Material Changes and Contingencies
The new employment agreements are not effective immediately. Their effectiveness is contingent upon the Company securing a new capital raise of at least $7 million by February 15, 2023 (or April 30, 2023, if audited financial statements are required). If this financing does not occur, the executives' prior employment contracts remain in full force and effect.
Outlook, Risks, and Management Commentary
The filing highlights a critical liquidity risk: the Company must secure $7 million in financing to activate the new executive compensation structure. The agreements include performance-based equity vesting tied to the completion of Phase 2 clinical trials for drug candidates Stenoparib or Dovitinib. The Company may need to seek shareholder approval to increase the number of options available under its 2021 Equity Incentive Plan if the proposed grants exceed current limits.
Investor Verification Checklist
- Verify whether the Company has secured the required $7 million "New Financing" by the February 15, 2023 deadline.
- Confirm the status of the Phase 2 clinical trials for Stenoparib or Dovitinib, which triggers additional equity vesting for the CEO.
- Review the Company's 2021 Equity Incentive Plan to determine if shareholder approval is needed for the proposed option grants.
- Monitor the Company's cash runway and liquidity position given the reliance on external capital for executive compensation activation.